entinostat and rrx-001
entinostat has been researched along with rrx-001 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fanger, G; Knox, S; Oronsky, B; Oronsky, N; Scicinski, J | 1 |
| Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K | 1 |
Reviews
2 review(s) available for entinostat and rrx-001
| Article | Year |
|---|---|
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Nitro Compounds; Oxidative Stress; Pyridines; Vorinostat | 2014 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid | 2016 |